Veru (NASDAQ:VERU) Releases Earnings Results, Hits Estimates

Veru (NASDAQ:VERU) posted its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.04), Fidelity Earnings reports. Veru had a negative net margin of 91.61% and a negative return on equity of 64.91%. The company had revenue of $9.73 million during the quarter, compared to the consensus estimate of $8.11 million. Veru updated its FY 2019 guidance to EPS.

Shares of VERU stock traded down $0.16 on Friday, reaching $1.96. The stock had a trading volume of 376,987 shares, compared to its average volume of 181,255. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.08. The stock’s 50-day moving average price is $2.22. The stock has a market capitalization of $134.37 million, a price-to-earnings ratio of -5.03 and a beta of 0.37. Veru has a 12 month low of $1.18 and a 12 month high of $2.49.

In other news, insider Mitchell Shuster Steiner sold 20,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $1.98, for a total value of $39,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 70,000 shares of company stock worth $152,400. 29.50% of the stock is owned by insiders.

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Veru in a research note on Monday, July 1st. They set an “overweight” rating and a $6.00 price objective for the company. ValuEngine upgraded shares of Veru from a “hold” rating to a “buy” rating in a research note on Friday, May 10th. Zacks Investment Research downgraded shares of Veru from a “buy” rating to a “hold” rating in a research note on Wednesday, April 17th. Brookline Capital Management began coverage on shares of Veru in a report on Monday, July 29th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.50 target price on shares of Veru in a report on Friday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $5.71.

About Veru

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Featured Story: What is Put Option Volume?

Earnings History for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with's FREE daily email newsletter.